Overview
This placebo-controlled trial assessed whether combining mometasone furoate (MFNS) and oxymetazoline (OXY) improves quality of life (QoL) in patients with seasonal allergic rhinitis (SAR). Subjects were randomized to one of several treatment arms: MFNS alone, OXY alone, MFNS + OXY once daily, MFNS + OXY three times daily, or placebo. The primary outcome was improvement in QoL as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
The Takeaways
-
Both combination groups (MFNS+OXY once daily and MFNS+OXY three times daily) demonstrated significantly greater QoL improvement versus placebo.
-
The MFNS+OXY three times daily group (MF+OXY3) showed the greatest QoL benefit, significantly outperforming MFNS monotherapy and OXY alone in overall RQLQ score and across all six key domains: activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, and emotional problems.
-
OXY monotherapy did not improve QoL significantly compared to placebo.
-
MFNS monotherapy also improved several QoL domains compared to placebo but was less effective than the MF+OXY3 combination.
Why It Matters
Allergic rhinitis can significantly impair day-to-day functioning, sleep, and emotional well-being. This study confirms that adding oxymetazoline to a corticosteroid like mometasone produces superior improvements in quality of life compared to either agent alone. The enhanced symptom relief across all life domains reinforces the value of thoughtfully combined intranasal therapies.
The Link to Allermi
Allermi’s personalized nasal spray formulations are built on this kind of clinical evidence—combining micro-dosed oxymetazoline with corticosteroids for maximal symptom control with minimal risk. This study supports Allermi’s approach of using targeted, multi-mechanism therapies to address SAR holistically—relieving congestion, improving sleep, and enhancing quality of life for patients suffering from seasonal allergies.
For more details, refer to the full study: Impact of Concomitant Administration of Mometasone Furoate and Oxymetazoline Nasal Sprays on Quality of Life in Subjects with Seasonal Allergic Rhinitis
